Igm Biosciences, INC Form 4 insider transactions
Elizabeth H.Z. Thompson, a director at IGM Biosciences, acquired 694 shares of common stock as partial payment of a quarterly retainer.
Director Kathleen Behrens reports acquiring 1,471 shares of IGM Biosciences common stock through fully vested restricted stock units.
Baker Bros. Advisors LP reports the acquisition of restricted stock units in IGM Biosciences on behalf of several entities due to director compensation.
Steven Weber, Principal Accounting Officer of IGM Biosciences, sold 1,701 shares of common stock on March 14, 2025, to cover tax withholding obligations related to vesting restricted stock units.
IGM Biosciences CFO Misbah Tahir sold 7,329 shares of common stock on March 14, 2025, to cover tax withholding obligations related to vesting restricted stock units.
IGM Biosciences CEO Mary Beth Harler sold 7,329 shares of common stock on March 14, 2025, to cover tax withholding obligations related to vesting restricted stock units.
Lisa Lynn Decker, Chief Business Officer of IGM Biosciences, sold shares to cover tax withholding obligations related to vesting restricted stock units.
IGM Biosciences' Principal Accounting Officer, Steven Weber, sold 1,122 shares of common stock to cover tax obligations related to vesting restricted stock units.
Director Jakob Haldor Topsoe acquired 1,734 shares of IGM Biosciences common stock as part of a quarterly retainer, while also indirectly holding a significant number of shares through Topsoe Holding A/S.
Director Christina Teng Topsoe acquired shares of IGM Biosciences through vested restricted stock units, according to a recent SEC filing.
Director Elizabeth H.Z. Thompson acquired 1,452 shares of IGM Biosciences common stock as part of a quarterly retainer payment.
IGM Biosciences director M Kathleen Behrens acquired 3,078 shares of common stock through a stock award, while also holding indirect ownership of a significant number of shares through various trusts.
Baker Bros. Advisors LP reports the acquisition of restricted stock units in IGM Biosciences on behalf of several entities due to director compensation.
Michael Lee, a director at IGM Biosciences, received 1,734 shares of common stock as a quarterly retainer, while also holding 11,056 shares indirectly through Redmile Group, LLC.
Redmile Group, through its managing director Michael Lee, received 1,734 shares of IGM Biosciences common stock as part of a quarterly retainer, while also ceasing to manage an account holding 120,347 shares.
IGM Biosciences' Principal Accounting Officer, Steven Weber, sold 539 shares of common stock to cover tax obligations related to vesting restricted stock units.
Lisa Lynn Decker, Chief Business Officer of IGM Biosciences, sold 1,063 shares of common stock to cover tax obligations related to vesting restricted stock units.
IGM Biosciences CEO, Mary Beth Harler, sold 1,708 shares of common stock to cover tax obligations related to vesting restricted stock units.
IGM Biosciences' Chief Financial Officer, Misbah Tahir, sold 1,708 shares of common stock to cover tax obligations related to vesting restricted stock units.
IGM Biosciences' Chief Financial Officer, Misbah Tahir, acquired 66,667 restricted stock units (RSUs) on November 18, 2024.
Form 4: IGM Biosciences Principal Accounting Officer Acquires 6,700 Shares Through Restricted Stock Units
IGM Biosciences' Principal Accounting Officer, Steven Weber, acquired 6,700 shares of common stock through restricted stock units.
IGM Biosciences CEO Mary Beth Harler reports acquisition of common stock and stock options.
Redmile Group, a significant shareholder in IGM Biosciences, reports acquiring additional shares through restricted stock units.
Director Michael Lee of IGM Biosciences reports acquisition of 1,734 shares of common stock as a quarterly retainer, with beneficial ownership disclaimed as he holds the securities on behalf of Redmile Group, LLC.
Director Jakob Haldor Topsoe reports acquiring 1,734 shares of IGM Biosciences common stock through fully vested restricted stock units.
Christina Teng Topsoe, a director of IGM Biosciences, acquired shares through the vesting of restricted stock units and also has indirect ownership through Topsoe Holding A/S and Pillarcater LLC.
Director Elizabeth Thompson acquired 1,452 shares of IGM Biosciences common stock on September 30, 2024, as part of a quarterly retainer.
Director Kathleen Behrens reports acquisition of shares via restricted stock units and indirect holdings through trusts.
Baker Bros. Advisors and related entities report the acquisition of IGM Biosciences common stock and restricted stock units (RSUs) due to director compensation policies.
Steven Weber, Principal Accounting Officer of IGM Biosciences, sold 469 shares of common stock on September 13, 2024, to cover tax withholding obligations related to vesting restricted stock units.